Voyager Therapeutics (VYGR) Common Equity (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Common Equity data on file, last reported at $173.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 36.32% year-over-year to $173.7 million; the trailing twelve-month figure through Mar 2026 stood at $173.7 million (down 36.32% YoY), and the FY2025 full-year result was $196.1 million, down 34.59% from the prior year.
• Common Equity slipped to $173.7 million in Q1 2026, from $196.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $340.9 million in Q1 2024 to a low of $59.0 million in Q4 2022.
• A 5-year average of $206.8 million and a median of $217.0 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 45.67% in 2022 and surged 300.41% in 2023, its largest moves.
• Tracing VYGR's Common Equity over 5 years: stood at $59.0 million in 2022, then surged by 300.41% to $236.3 million in 2023, then gained by 26.84% to $299.8 million in 2024, then tumbled by 34.59% to $196.1 million in 2025, then slipped by 11.43% to $173.7 million in 2026.
• Business Quant data shows VYGR's Common Equity at $173.7 million in Q1 2026, $196.1 million in Q4 2025, and $219.8 million in Q3 2025.